Extravasation of an antibody-drug conjugate: A case report of epidermal necrosis after trastuzumab-emtansine extravasation.
J Clin Pharm Ther
; 45(4): 832-835, 2020 Aug.
Article
em En
| MEDLINE
| ID: mdl-32412114
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Trastuzumab-emtansine is an antibody-drug conjugate developed to decrease off-target toxicity. According to the product label, reactions secondary to extravasation are mild or moderate. CASESUMMARY:
We report on a 51-year-old woman who developed epidermal necrosis after extravasation of trastuzumab-emtansine, which required surgical intervention. Six weeks later, the lesions were healed with residual hyperpigmentation. WHAT IS NEW ANDCONCLUSION:
We describe the course of a case of severe toxicity following trastuzumab-emtansine extravasation. We provide treatment recommendations and recommend amending the information on the product label on extravasation.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Imunoconjugados
/
Epiderme
/
Extravasamento de Materiais Terapêuticos e Diagnósticos
/
Ado-Trastuzumab Emtansina
/
Antineoplásicos
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article